| ￥4100 | |
| Z04824-100 | |
|
|
|
|
|
|
|
|
|
| Species | Cynomolgus | ||||
| Protein Construction |
|
||||
| Purity | > 95% as determined by BisTris PAGE | ||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||
| Biological Activity | Measured by its binding ability in a functional ELISA.Test result was comparable to standard batch. | ||||
| Expression System | HEK293 | ||||
| Theoretical Molecular Weight | 34.76 kDa (IL-12B) and 23.64 kDa (IL-12A) | ||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 45-48 kDa (IL-12B) and 38-44 kDa (IL-12A) based on Bis-Tris PAGE result. | ||||
| Formulation | Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). | ||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||
| Storage & Stability | Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles. |
Immobilized IL-12, His, Cynomolgus, His Tag at 0.5 μg/ml (100 μl/well) on the plate. Dose response curve for Anti-IL-12 Antibody, hFc Tag with the EC50 of 4.8ng/ml determined by ELISA. »
The purity of IL-12, His, Cynomolgus is greater than 95% as determined by SEC-HPLC. »
IL-12, His, Cynomolgus on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »
| Target Background | Interleukin 12 (IL-12) is a pleiotropic cytokine that plays an essential role in Th1-type immune response against cancer, a condition where cells in a particular part of the body grow and reproduce uncontrollably. |
| Synonyms | CLMF; CLMF2; IL-12A; IL-12B; IL12; IL12 p70; IMD28; IMD29; NFSK; NKSF1; NKSF2; P35; IL-12 subunit p35; IL12A; interleukin 12 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
